5,333 Danaher Corporation $DHR Shares Acquired by Investors Research Corp

Investors Research Corp increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 189.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,143 shares of the conglomerate’s stock after purchasing an additional 5,333 shares during the quarter. Investors Research Corp’s holdings in Danaher were worth $1,804,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new position in Danaher during the second quarter valued at $10,492,520,000. Jupiter Topco LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP bought a new position in Danaher during the 2nd quarter worth about $1,287,949,000. Bank of America Corp DE purchased a new position in Danaher during the second quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc bought a new position in shares of Danaher in the 2nd quarter worth $801,056,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

DHR traded up $3.24 during midday trading on Wednesday, hitting $218.85. 3,974,091 shares of the company traded hands, compared to its average volume of 4,460,003. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $153.85 billion, a price-to-earnings ratio of 38.87, a PEG ratio of 2.75 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The business has a 50 day simple moving average of $210.01 and a two-hundred day simple moving average of $194.05.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.77 earnings per share. On average, equities analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Analysts Set New Price Targets

Several brokerages have recently commented on DHR. UBS Group began coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. Barclays upped their target price on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Guggenheim increased their price target on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, TD Cowen dropped their target price on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $235.23.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.